Quizartinib (AC220): Selective FLT3 Inhibitor for AML Research

Executive Summary: Quizartinib (AC220) is a second-generation, highly selective FLT3 inhibitor validated for acute myeloid leukemia (AML) research. It blocks FLT3-ITD and wild-type forms at nanomolar IC₅₀ values (1.1 nM and 4.2 nM, respectively) [APExBIO, 2024]. The compound demonstrates approximately ten-fold selectivity for FLT3 over kinases like PDGFRα/β, KIT, RET, and CSF-1R (Song et al., 2025). Quizartinib's oral administration in mouse xenograft models significantly reduces FLT3 activity and tumor burden at doses as low as 1 mg/kg. Its favorable pharmacokinetics (C_max 3.8 μM at 2 h post-dose) and safety profile have been substantiated in both preclinical and clinical contexts. However, FLT3 resistance mutations may arise, highlighting the need for ongoing research into AML pathogenesis.

Biological Rationale

FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase frequently mutated in AML, particularly via internal tandem duplication (ITD) in the juxtamembrane domain. FLT3-ITD mutations drive constitutive kinase activation, promoting cell proliferation and survival. AML patients with FLT3-ITD mutations exhibit poor prognosis and high relapse rates. Targeting FLT3 signaling provides a strategic intervention point for AML research [mwinhibitor.com]. Quizartinib's selectivity and potency enable precise interrogation of FLT3-driven leukemogenesis and resistance mechanisms. This article extends the mechanistic detail outlined in previous reviews by focusing on resistance, workflow integration, and updated benchmarks.

Mechanism of Action of Quizartinib (AC220)

Quizartinib (AC220) is an ATP-competitive, type II tyrosine kinase inhibitor. It binds to the inactive (DFG-out) conformation of FLT3, blocking ATP binding and subsequent autophosphorylation. This inhibition disrupts downstream signaling pathways, notably STAT5, MAPK, and PI3K/AKT, which are implicated in AML cell survival and proliferation. Quizartinib inhibits both FLT3-ITD and wild-type FLT3 autophosphorylation in cell-based assays at low nanomolar concentrations. By blocking FLT3 activity, Quizartinib induces apoptosis and cell cycle arrest in FLT3-dependent AML cells. Resistance may develop through secondary mutations in the FLT3 kinase domain (e.g., F691L, D835Y), necessitating ongoing research into combination therapies and next-generation inhibitors.

Evidence & Benchmarks

• Quizartinib (AC220) inhibits FLT3-ITD with an IC₅₀ of 1.1 nM and wild-type FLT3 at 4.2 nM under cell-free kinase assay conditions (37°C, pH 7.4) (APExBIO).
• Shows ~10-fold selectivity for FLT3 versus kinases PDGFRα, PDGFRβ, KIT, RET, and CSF-1R (Song et al., 2025, DOI).
• Inhibits FLT3 signaling and cell proliferation in MV4-11 and RS4;11 AML cell lines at nanomolar concentrations (tki-258.com).
• Oral administration at 1 mg/kg in mouse FLT3-dependent xenograft models reduces FLT3 phosphorylation, extends survival, and can eradicate tumors (Song et al., 2025, DOI).
• Maximum plasma concentration (C_max) of 3.8 μM is reached within 2 hours post-dose in pharmacokinetic studies with good oral bioavailability (APExBIO).
• Demonstrates a favorable safety and PK profile in human studies, but resistance mutations in FLT3 (e.g., F691L, D835Y) have been observed clinically (flt-3.com).

Applications, Limits & Misconceptions

Quizartinib (AC220) is intended for research use in dissecting FLT3-driven AML biology, screening for resistance, and evaluating FLT3 signaling in vitro and in vivo. Its high selectivity and potency enable precise modeling of FLT3-dependent malignancy. This article clarifies that, while Quizartinib is powerful for cellular and animal studies, it is not approved for diagnostic or therapeutic use. It extends prior summaries (see mwinhibitor.com) by delineating workflow integration and highlighting resistance limitations.

Common Pitfalls or Misconceptions

• Quizartinib is not effective against FLT3-independent leukemia subtypes.
• Resistance can arise due to FLT3 kinase domain mutations (e.g., F691L, D835Y).
• Solutions are not recommended for long-term storage; use freshly prepared aliquots.
• Quizartinib is insoluble in water and ethanol; use DMSO for solubilization.
• For research use only; not for diagnostic or clinical applications.

Workflow Integration & Parameters

Quizartinib (AC220) is supplied as a solid by APExBIO. Store at -20°C. Dissolve at ≥28.03 mg/mL in DMSO for stock solutions; avoid water or ethanol. For cell-based assays, dilute to working concentrations in appropriate buffers; typical ranges are 1–100 nM. Use freshly prepared solutions; do not store for extended periods to avoid degradation. For in vivo studies, oral dosing at 1–10 mg/kg in mouse models is standard. Monitor FLT3 phosphorylation and downstream signaling as pharmacodynamic readouts. This article updates protocols in flt-3.com by providing exact solubility and pharmacokinetic benchmarks.

Conclusion & Outlook

Quizartinib (AC220) remains a gold standard for FLT3 inhibition in AML research due to its selectivity, potency, and well-characterized pharmacology. It enables mechanistic studies of FLT3 signaling, resistance pathways, and therapeutic modeling. Ongoing development of next-generation FLT3 inhibitors and combination strategies is necessary to address resistance mutations. For detailed protocols, product specifications, and ordering, refer to the Quizartinib (AC220) product page (A5793).